6533b7defe1ef96bd1276900
RESEARCH PRODUCT
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective Study
Sebastian BauerMargherita NanniniMarta SbaragliaMariella Spalato CerusoNadia HindiHeikki JoensuuPeter ReichardtAntoine ItalianoAngelo Paolo Dei TosJean-yves BlaySilvia GasperoniMarianna SillettaMaria Abbondanza PantaleoWinan J. Van HoudtGiuseppe ToniniPiotr RutkowskiRobin L. JonesGiovanni GrignaniSpyridon GennatasGiuseppe BadalamentiHans GelderblomPeter HohenbergerNikki S. IjzermanNeeltje SteeghsJavier Martin-brotoTommaso De PasAxel Le CesneMarta FioccoIngrid M.e. DesarPaolo G. CasaliAntonella BrunelloAndrea NapolitanoJohanna FalkenhorstBruno VincenziAlessandro GronchiElena FumagalliOlivier Mirsubject
STRUCTURAL BASISEXPRESSIONOncologyCancer Researchmedicine.medical_specialtyGastrointestinal Stromal Tumors3122 CancersMedizinAntineoplastic Agentsexon 9Adjuvants ImmunologicInternal medicinemedicineHumansFAILURERetrospective StudiesRISKRECEPTORGiSTProportional hazards modelbusiness.industryGASTROINTESTINAL STROMAL TUMORSHazard ratioImatinibRetrospective cohort studyExonsAdjuvant treatmentConfidence intervalGENOTYPEProto-Oncogene Proteins c-kitOncologyChemotherapy AdjuvantMutationPropensity score matchingCohortImatinib MesylateNeoplasm Recurrence LocalTYROSINE KINASE INHIBITORbusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]medicine.drugGISTdescription
[Purpose] The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9–mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-04-15 |